GE Healthcare working ‘two to three years’ ahead anticipating manufacturing advances

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Smshoot)
(Image: Getty/Smshoot)

Related tags: Ge healthcare, G-CON

The rapid evolution of cell and gene therapy technology is leading GE Healthcare to explore partnerships to meet increasing manufacturing demand, according to the company's enterprise solutions leader.

In January, GE Healthcare and G-CON announced​ that they would combine capabilities to offer prefabricated manufacturing platforms. The partnership arrived shortly after GE Healthcare worked with Lonza​ to set up a biologics facility in China.

Greg Crescenzi, enterprise solutions leader for cell & gene therapy at GE Healthcare, told us that partnerships are an important strategy for contract manufacturing organisations (CMOs) to meet demand.

Crescenzi explained that 40% year-on-year growth seen in the sector throws up new challenges, including how to supply the industry when related technology is developing rapidly.

“We must anticipate what therapeutic manufacturing models will look like in two to three years and design tools and pursue partnerships that will allow us to meet manufacturing needs,”​ he explained.

According to Crescenzi, this was the motivation behind the partnership with G-CON, by enabling a unique offering of a single, ready-made facility to provide the materials needed to progress drug candidates from the clinical trial stage to commercialisation.

“It provides customers with an entire cleanroom infrastructure from a single source and will improve and accelerate cell therapy and viral manufacturing on a good manufacturing practice (GMP) scale,”​ he said.

Related news

Show more

Related products

show more

Strategies for Upstream Intensification

Strategies for Upstream Intensification

Take the Right Path Upstream with MilliporeSigma | 01-Sep-2020 | Technical / White Paper

The Facility of the Future represents a transformation in how biologics are developed and manufactured.

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 05-Aug-2020 | Technical / White Paper

Traditional methods for adventitious agent testing rely on biological amplification and detection, which can take several weeks. This time-consuming approach...

Related suppliers

Follow us

Products

View more

Webinars